Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
en-TEAR is a microbiome-based nutraceutical formulation developed by ENBIOSIS Biotechnology to support eye health via the gut-eye axis. Designed using an AI-powered digital twin platform and a retrosynthesis engine, the formulation utilizes food-grade precursors that are metabolized by the gut microbiota to produce beneficial metabolites, such as short-chain fatty acids, which help modulate systemic inflammation. en-TEAR is clinically shown to support tear production, improve tear film stability, reduce ocular surface inflammation, and alleviate dry eye symptoms. It is commercialized as a retail-ready product in powder and bar formats, and is also undergoing a randomized controlled trial for evaporative dry eye disease and Meibomian gland dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on en-TEAR.